CASI CASI Pharmaceuticals Inc
5,874
$2.83
$0.035
(1.25%)
| Watchers | 5,874 |
| 52-Wk Low | $1.85 |
| 52-Wk High | $8.48 |
| Market Cap | $37.46M |
| Volume | 2,077.00 |
| 52-Wk High | $8.48 |
| 52-Wk Low | $1.85 |
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASPR Newswire • 28 days ago
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR Newswire BEIJING, April 8, 2024...
Share to Feed
Stock analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) in a note issued to investors on Friday. The firm set a "hold" rating on the...
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...
CASI Pharmaceuticals, Inc. (NASDAQ:CASI Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 127,300 shares, a growth of...
StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI Free Report) in a research note published on Tuesday morning. The firm issued a hold rating on the biotechnology...
Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China CASI Pharmaceuticals Report Positive Interim...
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy...